TRAVERE THERAPEUTICS INC's ticker is TVTX and the CUSIP is 89422G107. A total of 138 filers reported holding TRAVERE THERAPEUTICS INC in Q2 2021. The put-call ratio across all filers is 0.71 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $631,343 | -41.8% | 70,620 | 0.0% | 0.00% | – |
| Q2 2023 | $1,084,723 | -18.7% | 70,620 | +19.0% | 0.00% | -100.0% |
| Q1 2023 | $1,334,107 | +6.9% | 59,320 | 0.0% | 0.00% | 0.0% |
| Q4 2022 | $1,247,500 | -14.7% | 59,320 | -0.0% | 0.00% | 0.0% |
| Q3 2022 | $1,462,000 | +1.7% | 59,333 | 0.0% | 0.00% | 0.0% |
| Q2 2022 | $1,438,000 | -6.0% | 59,333 | +0.0% | 0.00% | 0.0% |
| Q1 2022 | $1,529,000 | -16.8% | 59,320 | +0.2% | 0.00% | 0.0% |
| Q4 2021 | $1,838,000 | +28.0% | 59,220 | 0.0% | 0.00% | 0.0% |
| Q3 2021 | $1,436,000 | +54.9% | 59,220 | -6.8% | 0.00% | – |
| Q2 2021 | $927,000 | -73.6% | 63,520 | -54.8% | 0.00% | -100.0% |
| Q1 2021 | $3,513,000 | +102.9% | 140,680 | +121.5% | 0.00% | +100.0% |
| Q4 2020 | $1,731,000 | – | 63,520 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Lynx1 Capital Management LP | 411,680 | $10,609,000 | 9.85% |
| VR Adviser, LLC | 1,994,997 | $51,411,000 | 8.33% |
| Kynam Capital Management, LP | 870,918 | $22,444,000 | 7.28% |
| GREAT POINT PARTNERS LLC | 1,010,000 | $26,028,000 | 6.29% |
| Deep Track Capital, LP | 3,134,503 | $80,776,000 | 5.18% |
| RA Capital Management | 4,922,941 | $126,864,000 | 2.77% |
| ARMISTICE CAPITAL, LLC | 4,958,000 | $127,768,000 | 2.47% |
| MPM BioImpact LLC | 277,950 | $7,163,000 | 1.92% |
| Sofinnova Investments, Inc. | 658,249 | $16,963,000 | 1.29% |
| Perceptive Advisors | 1,845,555 | $47,560,000 | 0.95% |